Harbour BioMed, Vir to develop new therapies

By The Science Advisory Board staff writers

Harbour Biomed (HBM) and Vir Biotechnology have partnered to research and develop novel immuno-oncology and infectious disease therapies.

The partnership will leverage the scientific expertise at both companies in order to develop immunotherapies for patients with cancer and infectious disease. It will also utilize HBM's Harbour Mice technology to generate antibodies for the experiments.

Copyright © 2020 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking